Investigating Clofazimine for LE Lesions

Abstract

Few well-controlled, randomized studies have compared therapeutic agents for cutaneous lesions of lupus erythematosus (LE). Antimalarial agents such as chloroquine are FDA-approved and considered effective but can be toxic, particularly with chronic use. An equally effective but nontoxic alternative would be a welcome addition to our therapeutic armamentarium. Clofazimine is approved for the treatment of leprosy and erythema nodosum leprosum but has limited distribution in the U.S. These authors compared clofazimine with chloroquine for treating 33 patients …